Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24566823 | 0.86 | DGAT1 (0.32) | GSK3AGSK3BDGAT1 | |
| SCHEMBL27215292 | 0.85 | GSK3A (0.32) | GSK3AGSK3BAAK1 | |
| SCHEMBL24566903 | 0.85 | GSK3A (0.32) | GSK3AGSK3B | |
| SCHEMBL27215120 | 0.85 | DGAT1 (0.34) | GSK3AGSK3BDGAT1AAK1 | |
| SCHEMBL16516928 | 0.85 | GSK3A (0.37) | GSK3AGSK3BDGAT1 | |
| SCHEMBL29705492 | 0.85 | DGAT1 (0.34) | GSK3AGSK3BDGAT1AAK1 | |
| SCHEMBL16532457 | 0.83 | GSK3A (0.38) | GSK3AGSK3BDGAT1 | |
| SCHEMBL13406942 | 0.81 | IRAK4 (0.34) | GSK3AGSK3B | |
| SCHEMBL68598 | 0.80 | DGAT1 (0.34) | GSK3AGSK3BDGAT1AAK1 | |
| SCHEMBL3375859 | 0.80 | MERTK (0.35) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| WO-2022159745-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | GSK3A 588/4885GSK3B 547/4885DGAT1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.